Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths
出版年份 2022 全文链接
标题
Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths
作者
关键词
-
出版物
BIOMEDICINE & PHARMACOTHERAPY
Volume 153, Issue -, Pages 113363
出版商
Elsevier BV
发表日期
2022-07-12
DOI
10.1016/j.biopha.2022.113363
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species
- (2020) Shuai Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- HIF-1α promotes the migration and invasion of hepatocellular carcinoma cells via the IL-8–NF-κB axis
- (2018) Wenming Feng et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
- (2018) Shuhei Shinoda et al. Oncotarget
- Role of Mitochondria in Ferroptosis
- (2018) Minghui Gao et al. MOLECULAR CELL
- Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
- (2017) I. Walter et al. MEDICAL ONCOLOGY
- NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway
- (2017) Arundhati Jana et al. Oncotarget
- Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways
- (2016) Qichao Huang et al. Autophagy
- Iron depletion enhances the effect of sorafenib in hepatocarcinoma
- (2016) Shinichi Urano et al. CANCER BIOLOGY & THERAPY
- Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
- (2016) Naoki Yamamoto et al. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
- Fluorescence probes to detect lipid-derived radicals
- (2016) Ken-ichi Yamada et al. Nature Chemical Biology
- Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
- (2016) Issei Saeki et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The potential of deferasirox as a novel therapeutic modality in gastric cancer
- (2016) Jung Hye Choi et al. World Journal of Surgical Oncology
- Hsp90 modulates the stability of MLKL and is required for TNF-induced necroptosis
- (2016) X M Zhao et al. Cell Death & Disease
- Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model
- (2016) John Chun-Hao Chen et al. Oncotarget
- Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis
- (2014) A. Ramírez-Labrada et al. Clinical & Translational Oncology
- Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
- (2014) Scott J Dixon et al. eLife
- Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib
- (2013) Christophe Louandre et al. INTERNATIONAL JOURNAL OF CANCER
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
- (2012) Scott J. Dixon et al. CELL
- OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma
- (2012) Xiangxuan Zhao et al. LABORATORY INVESTIGATION
- Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo
- (2011) Yu-Cheng Kuo et al. BIOMEDICINE & PHARMACOTHERAPY
- Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
- (2011) L Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies
- (2011) Q. Ba et al. CLINICAL CANCER RESEARCH
- Deferoxamine for Advanced Hepatocellular Carcinoma
- (2011) Takahiro Yamasaki et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
- (2010) E. Messa et al. HAEMATOLOGICA
- NF-κB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy
- (2009) Jian-Min Wu et al. CANCER LETTERS
- A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan
- (2008) Keisuke Miyazawa et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More